Connecting to SEC EDGAR… PricingSign in
← All filings
Kardigan, Inc.KARD · Nov 6, 4:06 PM ET

Kardigan completes KATALYST-AV enrollment; endpoint assessed at Week 48

Kardigan completed enrollment in its Phase 2b KATALYST-AV aortic stenosis trial, with the primary endpoint now assessed at Week 48 and topline data expected 2H 2027.

AI-generated summary, checked against the filing. Can contain errors: read the original filing ↗. Not investment advice.